fda compounding semaglutide enforcement news november 2025 pharmacies to halt sales May 22 FDA and Novo Nordisk Warned

FDA Review Timelines For Orforglipron And Amycretin The pipeline for new oral GLP-1 drugs is active, with several candidates moving through the FDA review process

Retatrutide is still an investigational compound, not an approved commercial medicine currently available to the public in Australia

Frias JP et al (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens

Today, it is part of a growing cohort of brands targeting the GLP-1 food space with prebiotic fibre

When you do a heavy set of squats, the first few seconds of that effort are fueled by ATP regenerated from the phosphocreatine pool

Some research suggests that GLP-1 agonists may have anti-inflammatory effects that could theoretically influence the autoimmune process itself, though this remains speculative and has not been demonstrated in clinical trials specifically for thyroid autoimmunity